ADC Therapeutics America, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$14.7M
Doctors Paid
5,007
Transactions
13,657
2024 Total
$5.1M
Payment Breakdown by Category
Research$11.1M (75.5%)
Consulting$1.6M (10.8%)
Food & Beverage$338,909 (2.3%)
Travel$245,684 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.1M | 1,885 | 75.5% |
| Consulting Fee | $1.6M | 322 | 10.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 374 | 7.3% |
| Food and Beverage | $338,909 | 10,208 | 2.3% |
| Travel and Lodging | $245,684 | 703 | 1.7% |
| Honoraria | $225,504 | 90 | 1.5% |
| Space rental or facility fees (teaching hospital only) | $104,795 | 31 | 0.7% |
| Education | $24,990 | 44 | 0.2% |
Payments by Type
Research
$11.1M
1,885 transactions
General
$3.6M
11,772 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) | $2.1M | 0 | 243 |
| A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5) | $1.1M | 0 | 161 |
| A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | $998,686 | 0 | 110 |
| A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid | $969,732 | 0 | 133 |
| ADCT-601-102 | $949,064 | 0 | 547 |
| A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2) | $792,580 | 0 | 103 |
| A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3) | $753,216 | 0 | 80 |
| ADCT-901-101 | $627,002 | 0 | 303 |
| A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS 7) | $393,746 | 0 | 39 |
| A Phase 2 Open-label | $390,399 | 0 | 42 |
| IIT_Strati_ADCT-402-1 | $276,071 | 0 | 4 |
| A Study to Evaluate the Safety | $269,587 | 0 | 15 |
| IIT_Hill_ADCT-402-1 | $251,268 | 0 | 6 |
| ADCT-402 | $229,530 | 0 | 6 |
| IIT_Tuscano_ADCT-402-1 | $187,507 | 0 | 9 |
| A Phase 2 Open-label Study of | $177,375 | 0 | 16 |
| A Phase 1b, Open-Label, Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With R-CHOP in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) | $139,599 | 0 | 10 |
| A Phase 2 Randomized Study of Loncastuximab Tesirine Versus Idelalisib in Patients With Relapsed or Refractory Follicular Lymphoma (LOTIS 6) | $118,511 | 0 | 14 |
| IIT_Kambhampati_ADCT-402-1 | $89,343 | 0 | 3 |
| IIT_Smith_ADCT-402-1 | $86,899 | 0 | 5 |
| ADCT-901 | $68,179 | 0 | 31 |
| Study ofADCT-301in Patients With Selected Advanced Solid Tumors | $25,362 | 0 | 4 |
| A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors | $884.25 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Cyrus Khan, M.d, M.D | Hematology & Oncology | Pittsburgh, PA | $113,993 | $0 |
| Yogesh Jethava, Md, MD | Hematology | Park Ridge, IL | $96,007 | $0 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $88,928 | $0 |
| Dr. Sayed Mehdi Hamadani, M.d, M.D | Hematology & Oncology | Milwaukee, WI | $82,929 | $0 |
| Adolfo Diaz, Md, MD | Hospitalist | San Antonio, TX | $76,816 | $0 |
| Joshua Brody, M.d, M.D | Hematology & Oncology | New York, NY | $71,866 | $0 |
| Dr. Christopher Maisel, Md, MD | Hematology & Oncology | Dallas, TX | $70,027 | $0 |
| Amitkumar Mehta | Hematology & Oncology | Birmingham, AL | $58,922 | $0 |
| Dr. Anil Tulpule, M.d, M.D | Hematology & Oncology | Los Angeles, CA | $58,608 | $0 |
| Dr. Sameh Gaballa, Md, MD | Medical Oncology | Tampa, FL | $53,241 | $0 |
| Dr. Amit Mehta, M.d, M.D | Hematology & Oncology | Cary, NC | $49,435 | $0 |
| Emily Ayers, Md, MD | Hematology | Charlottesville, VA | $47,643 | $0 |
| Daniel Greenwald, M.d, M.D | Medical Oncology | Santa Barbara, CA | $46,039 | $0 |
| Dr. Suzanne Fanning, D.o, D.O | Hematology & Oncology | Greenville, SC | $41,686 | $0 |
| Dr. Mark Fesler, Md, MD | Internal Medicine | Saint Louis, MO | $40,276 | $0 |
| Melhem Solh, M.d, M.D | Specialist | Atlanta, GA | $40,041 | $0 |
| Sairah Ahmed, Md, MD | Hematology & Oncology | Houston, TX | $39,638 | $0 |
| Dr. Nakhle Saba, Md, MD | Specialist | Baton Rouge, LA | $38,866 | $0 |
| Dr. Olalekan Oluwole, Md, Mph, MD, MPH | Hospitalist | Nashville, TN | $38,345 | $0 |
| Dr. Alan Zausner Skarbnik, Md, MD | Hematology & Oncology | Charlotte, NC | $37,966 | $0 |
| Dr. Tycel Phillips, M.d, M.D | Internal Medicine | Duarte, CA | $36,662 | $0 |
| Kayla Wilson, Aprn, APRN | Family | Louisville, KY | $35,871 | $0 |
| Dr. Matthew Mckinney, M.d, M.D | Hematology & Oncology | Durham, NC | $34,602 | $0 |
| Kami Maddocks, Md, MD | Hematology | Columbus, OH | $31,610 | $0 |
| Eduardo Sotomayor, Md, MD | Hematology & Oncology | Tampa, FL | $27,529 | $0 |
Ad
Payment Categories
- Food & Beverage $338,909
- Consulting $1.6M
- Travel & Lodging $245,684
- Research $11.1M
About ADC Therapeutics America, Inc.
ADC Therapeutics America, Inc. has made $14.7M in payments to 5,007 healthcare providers, recorded across 13,657 transactions in the CMS Open Payments database. In 2024, the company paid $5.1M.
Payments were distributed across 82 medical specialties. The top specialty by payment amount is Hematology & Oncology ($1.6M to 1,444 doctors).
Payment categories include: Food & Beverage ($338,909), Consulting ($1.6M), Research ($11.1M), Travel & Lodging ($245,684).